KSI-301 + Aflibercept
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Wet Age-related Macular Degeneration
Conditions
Wet Age-related Macular Degeneration
Trial Timeline
Jun 23, 2021 → Apr 6, 2023
NCT ID
NCT04964089About KSI-301 + Aflibercept
KSI-301 + Aflibercept is a phase 3 stage product being developed by Kodiak Sciences for Wet Age-related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT04964089. Target conditions include Wet Age-related Macular Degeneration.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04964089 | Phase 3 | Completed |
| NCT04611152 | Phase 3 | Terminated |
| NCT04603937 | Phase 3 | Terminated |
| NCT04592419 | Phase 3 | Completed |
| NCT04049266 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Wet Age-related Macular Degeneration